Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review
Hyeong Su Kim, Jung Han Kim, Hyun Joo Jang · Journal of Cancer · 2019
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · review · 2019
Abstract
Fibroblast growth factor receptor-2 (FGFR2) gene is amplified in up to 15% of patients with gastric cancer (GC).However, the prognostic significance of FGFR2 amplification has been controversial.This meta-analysis was conducted to evaluate the clinicopathological impacts of FGFR2 amplification in patients with GC.We performed a systematic computerized search of the electronic databases of PubMed, PMC, EMBASE, Web of Science, and Google Scholar and selected studies assessing the correlation of FGFR2 amplification with pathologic features and/or prognosis in gastric adenocarcinoma.From eight studies, 2,377 patients were included in the pooled analysis of odds ratios (ORs) with 95% confidence intervals (CIs) for pathologic findings and hazard ratios (HRs) with 95% CIs for overall survival.FGFR2 amplification was significantly associated with LN metastasis (OR = 3.93, 95% CI: 2.22-6.96,p < 0.00001) and poorly differentiated adenocarcinoma (OR = 2.36, 95% CI: 1.03-5.39,p = 0.04).In addition, patients with GC harboring FGFR2 amplification showed significantly worse survival (HR = 2.09, 95% CI: 1.68-2.59,p < 0.00001), compared with patients with FGFR2-unamplified GC.In conclusion, this meta-analysis indicates that FGFR2 amplification is an adverse prognostic factor in patients with GC.
Open the resolved locator · 10.7150/jca.29184
Metadata licence: OpenAlex metadata (CC0)